Form 4: Intra-Cellular Therapies Director Salas Disposes of Shares and Options Following Merger with Johnson & Johnson

Director Eduardo Rene Salas reports the disposal of Intra-Cellular Therapies shares and cancellation of stock options following the company's merger with Johnson & Johnson, where shareholders received $132 per share.

Summary

• Eduardo Rene Salas, a director of Intra-Cellular Therapies, Inc., filed a Form 4 detailing changes in beneficial ownership.
• The filing reports the disposal of common stock and cancellation of stock options due to the merger between Intra-Cellular Therapies and Johnson & Johnson, effective April 2, 2025.
• Each share of Intra-Cellular Therapies common stock was converted into the right to receive $132 in cash.
• Outstanding stock options with an exercise price less than $132 were canceled and converted into the right to receive cash equal to the difference between $132 and the exercise price.
• Options with an exercise price equal to or exceeding $132 were canceled for no consideration.
• Restricted stock units (RSUs) were canceled and converted into the right to receive cash equal to $132 per underlying share, with certain RSUs granted in 2025 payable at the original vesting date, subject to accelerated vesting in some cases.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document simply reports the completion of a merger and the resulting transactions. It doesn't convey positive or negative implications beyond the factual events.

Future Outlook

The company is now a wholly-owned subsidiary of Johnson & Johnson.

Industry Context

This announcement reflects a major pharmaceutical company, Johnson & Johnson, acquiring a smaller biotech firm, Intra-Cellular Therapies, likely to expand its portfolio of drugs and intellectual property.

Comparison to Industry Standards

• Mergers and acquisitions are common in the pharmaceutical industry, with acquisition prices often based on the target company's pipeline, existing products, and market potential.
• The $132 per share valuation would be compared to other recent acquisitions in the biotech space to assess whether it was a fair price.
• Comparable companies could include other biotech firms with similar drug development stages and market focus.

Stakeholder Impact

• Shareholders received $132 per share in cash.
• Employees may experience changes as the company integrates into Johnson & Johnson.

Key Dates

Keywords

Form 4, Intra-Cellular Therapies, Johnson & Johnson, Merger, Beneficial Ownership, Director, Stock Options, Restricted Stock Units, ITCI